Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
32 studies found for:    ponatinib
Show Display Options
Rank Status Study
1 Recruiting Ponatinib for FLT3-ITD Acute Myelogenous Leukemia
Condition: Acute Myeloid Lukemia
Intervention: Drug: Ponatinib and Cytarabine
2 Active, not recruiting Ponatinib as Second Line Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib, Dasatinib or Nilotinib
Condition: Leukemia
Intervention: Drug: Ponatinib
3 Terminated
Has Results
Ponatinib for Squamous Cell Lung and Head and Neck Cancers
Condition: Non-Small Cell Lung Cancer, Head and Neck Cancer
Intervention: Drug: ponatinib
4 Withdrawn Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma
Condition: Endometrial Neoplasms
Intervention: Drug: Ponatinib
5 Approved for marketing Expanded Access Program of Ponatinib
Conditions: Chronic Myeloid Leukemia (CML);   Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Intervention: Drug: ponatinib
6 Recruiting Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
Conditions: Adenocarcinoma of the Lung;   Extensive Stage Small Cell Lung Cancer;   Limited Stage Small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Intervention: Drug: Ponatinib
7 Terminated Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
Condition: Leukemia
Intervention: Drug: Ponatinib
8 Active, not recruiting A Phase 1/2 Study of Ponatinib in Japanese Patients With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Conditions: Chronic Myeloid Leukemia (CML);   Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Interventions: Drug: ponatinib - Phase 1;   Drug: ponatinib - Phase 2
9 Recruiting Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
Condition: Glioblastoma
Intervention: Drug: Ponatinib
10 Recruiting A Study Comparing Ponatinib and Nilotinib in Patients With Chronic Myeloid Leukemia
Condition: Chronic Phase Chronic Myeloid Leukemia
Interventions: Drug: ponatinib 30 mg QD;   Drug: ponatinib 15 mg QD;   Drug: nilotinib 400 mg BID
11 Recruiting Ponatinib in Advanced NSCLC w/ RET Translocations
Condition: Non Small Cell Lung Cancer
Intervention: Drug: Ponatinib
12 No longer available Compassionate Use Ponatinib
Conditions: Philadelphia Chromosome Positive (Ph+) Leukemias;   Chronic Myeloid Leukemia
Intervention: Drug: Ponatinib
13 Recruiting Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
Conditions: Chronic Myeloid Leukemia;   Chronic Phase;   Adults
Intervention: Drug: Ponatinib
14 Recruiting Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
Condition: Malignant Neoplasm
Interventions: Drug: ponatinib hydrochloride;   Other: laboratory biomarker analysis
15 Active, not recruiting Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
Conditions: Chronic Myeloid Leukemia;   Ph+ Acute Lymphoblastic Leukemia
Intervention: Drug: Ponatinib
16 Recruiting Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.
Conditions: Philadelphia Positive;   BCR-ABL Positive;   Acute Lymphoblastic Leukemia
Intervention: Drug: Ponatinib
17 Recruiting Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses
Condition: Myeloid Leukemia, Chronic, Chronic Phase
Interventions: Drug: ponatinib 45 mg;   Drug: ponatinib 30 mg;   Drug: ponatinib 15 mg
18 Not yet recruiting Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
Conditions: Leukemia;   FLT3-Mutated Acute Myeloid Leukemia;   FLT3-Mutated High-Risk Myelodysplastic Syndrome
Interventions: Drug: Ponatinib;   Drug: 5-azacytidine;   Behavioral: Phone Calls
19 Recruiting Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions
Condition: Malignant Hepatobiliary Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Ponatinib Hydrochloride;   Other: Quality-of-Life Assessment
20 Completed
Has Results
A Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Condition: GIST
Intervention: Drug: ponatinib

   Previous Page Studies Shown (1-20) Next Page (21-32) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.